What is HC Wainwright's Forecast for JANX FY2024 Earnings?

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Janux Therapeutics in a research note issued on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.36) per share for the year, down from their prior estimate of ($1.21). HC Wainwright currently has a "Buy" rating and a $63.00 price target on the stock. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.95) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($2.48) EPS and FY2028 earnings at ($0.62) EPS.

A number of other equities analysts have also weighed in on JANX. UBS Group started coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $69.00 target price on the stock. Scotiabank decreased their target price on Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday. Wedbush restated an "outperform" rating and issued a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Stifel Nicolaus started coverage on Janux Therapeutics in a research note on Friday, September 6th. They issued a "buy" rating and a $70.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $66.44.

Janux Therapeutics Stock Down 0.4 %

Shares of NASDAQ:JANX traded down $0.24 during midday trading on Monday, reaching $53.68. 1,011,505 shares of the company traded hands, compared to its average volume of 715,061. Janux Therapeutics has a 12 month low of $5.80 and a 12 month high of $65.60. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -44.62 and a beta of 3.52. The firm's fifty day moving average price is $49.02 and its two-hundred day moving average price is $46.35.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The company's revenue for the quarter was down 82.6% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JANX. Plato Investment Management Ltd increased its holdings in shares of Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company's stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics in the 2nd quarter worth $29,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics in the 2nd quarter worth $151,000. Institutional investors own 75.39% of the company's stock.

Insider Transactions at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the company's stock in a transaction on Friday, October 18th. The stock was acquired at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now owns 9,317,246 shares in the company, valued at $416,946,758.50. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the sale, the insider now owns 3,162,851 shares of the company's stock, valued at approximately $132,839,742. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 420,610 shares of company stock worth $19,288,666. 29.40% of the stock is currently owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.